Vimarsana
Biggest News Aggregation in the World

Page 13 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Vimarsana News

FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

LYNPARZA combination showed a clinically meaningful reduction in risk of disease progression or death in these patients in the Phase 3 PROpel trial First approval of a PARP inhibitor in combination... | June 1, 2023

Lynparza and Abiraterone Approved for BRCA-Mutated Prostate Cancer in US - Vimarsana News

Lynparza and Abiraterone Approved for BRCA-Mutated Prostate Cancer in US

Miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

AstraZeneca discontinues brazikumab; Lynparza wins approval - Vimarsana News

AstraZeneca discontinues brazikumab; Lynparza wins approval

AstraZeneca PLC on Thursday hailed another approval for cancer drug Lynparza, while it ceased its development programme for Crohn's disease-focused brazikumab. The Cambridge-based pharmaceutical... | June 1, 2023

LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer - Vimarsana News

LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

LYNPARZA combination reduced the risk of disease progression or death by 76% vs. abiraterone alone First PARP inhibitor approved in combination with a novel hormonal agent underscores clinically... | June 1, 2023

FDA Approves Olaparib Combination to Treat BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer - Vimarsana News

FDA Approves Olaparib Combination to Treat BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Olaparib plus abiraterone and prednisone or prednisolone already is approved in the European Union and several other countries.

Source: ajmc.com